Joshua Solomon, ACR 2021: Efficacy of Pirfenidone in Rheumatoid Arthritis Interstitial Lung Disease
Dr Joshua Solomon (National Jewish Health, Denver, CO, USA) kindly took the time to discuss the findings from the randomized, double-blinded, placebo-controlled TRAIL1 trial (NCT02808871) which investigated the safety, tolerability and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease‘ (ABSTRACT NUMBER: L10) was presented at the ACR Convergence, 5-9 November 2021.
- Could you tell us a little about rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its incidence, and unanswered questions in its treatment? (0:12)
- What were the aims and design of the TRAIL1 study? (0:53)
- What issues were experienced with recruitment? (1:26)
- What were the primary and secondary endpoints and how well were these achieved? (2:13)
- Which patients were most likely to respond to pirfenidone? (3:07)
Disclosures: Dr Joshua Solomon has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatic Diseases
Machine-learning models as predictors of fractures in osteoporosis: Giovanni Adami, WCO-IOF-ESCEO 2023
In this study a machine-learning approach was investigated over two years to determine the efficacy of fracture risk prediction in osteoporosis. touchIMMUNOLOGY were delighted to speak with Dr. Giovanni Adami (University of Verona, Verona, Italy) to discuss the machine-learning models already available for screening osteoporosis and their limitations, the risk factors used as predictors of […]
Patrick Durez, ACR 2022: Factors associated with disease flare following COVID vaccination in inflammatory rheumatic and musculoskeletal diseases
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry registered patients with pre-existing rheumatic and musculoskeletal diseases, who have been vaccinated against COVID-19. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) to discuss the aims, methodology and findings of this study looking at factors associated […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!